• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Riociguat(625115-55-1)
Methyl [4,6-diaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]carbaMate
2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine(428854-24-4)
4,6-PyriMidinediaMine, 2-[1-[(2-fluorophenyl)Methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(phenylazo)-
1H-Pyrazolo[3,4-b]pyridine-3-carboximidamide, 1-[(2-fluorophenyl)methyl]-, hydrochloride (1:1)
1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide(256376-68-8)

US FDA approves Natco’s ANDA for generic version of Vidaza

expressbpdJune 29, 2017

Tag: FDA , Natco’s ANDA  ,  Vidaza

                                                      

Natco Pharma has got the final approval for Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (FDA) for the generic version of Vidaza (Azacitidine for injection, 100 mg per vial), single-dose vial.

According to a company statement, Natco and its marketing partner Breckenridge Pharmaceutical, Inc. (BPI) plan to launch the product in the US market in the near future.

Vidaza by Celgene Corporation is a prescription anti-cancer chemotherapy drug that is indicated to treat, myelodysplastic syndrome (MDS).Vidaza generated total combined sales of $188 million for the 12-month period ended April 2017, based on industry sales data.

Previous:Zydus Cadila to market oxybutynin chloride tablets

Next:QS Pharma receives EMA approval for medicinal products manufacturing

Related News

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

PRNewswireDecember 23, 2024

SCG Cell Therapy Pte Ltd (SCG),announced the signing of a Memorandum of Understanding (MoU) with A*STAR BTI and NATi to advance RNA-based therapeutics manufacturing process development and clinical translation.

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

US FDA approves Natco’s ANDA for generic version of Vidaza | Pharmasources.com

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

You may like
More>>

Tacrolimus (FDA)

Tacrolimus (FDA)
99% up, DMF, FDA (zero defect) Emtricitabine 143491-57-0

99% up, DMF, FDA (zero defect) Emtricitabine 143491-57-0
Compliance FDA 21 part 11 Packaging leak tester for pharmaceuticals

Compliance FDA 21 part 11 Packaging leak tester for pharmaceuticals
Mitomycin ( FDA)

Mitomycin ( FDA)
Aciclovir (FDA)

Aciclovir (FDA)
HFHA(m-6FDAP)

HFHA(m-6FDAP)
High quality Stability Chamber(FS/CFS Series:FDA)

High quality Stability Chamber(FS/CFS Series:FDA)
Ifosfamide (FDA)

Ifosfamide (FDA)
Bumetanide (FDA)

Bumetanide (FDA)
Vitamine B12 (FDA)

Vitamine B12 (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service